Published ahead of print on April 30, 2009, doi:10.1164/rccm.200808-1250OC Am. J. Respir. Crit. Care Med., Volume 180, Number 2, July 2009, 159-166 A more recent version of this article appeared on July 15, 2009
Submitted on August 9, 2008 Human Neutrophil Peptides and Phagocytic Deficiency in Bronchiectatic LungsStefanos Voglis1,1 The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada; Departments of Anaesthesia and Physiology, Interdepartmental Division of Critical Care Medicine and, Division of Respiratory Medicine, University of Toronto, Toronto, Canada, 2 The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada; Division of Respiratory Medicine, University of Toronto, Toronto, Canada, 3 Department of Physiology, University of Toronto, Toronto, Canada; Division of Respiratory Medicine, University of Toronto, Toronto, Canada, 4 Department Medicine, Centre Hospitalier Universitaire de Sherbrooke, Quebec, Canada, 5 The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada; Division of Respiratory Medicine, University of Toronto, Toronto, Canada, 6 Division of Respiratory Medicine, University of Toronto, Toronto, Canada; Integrated Department of Immunology, National Jewish Health, Denver, Colorado, United States * To whom correspondence should be addressed. E-mail: zhangha{at}smh.toronto.on.ca.
Abstract (word count: 246) Rationale: A well-known clinical paradox is that severe bacterial infections persist in the lungs of cystic fibrosis (CF) patients despite the abundance of polymorphonuclear neutrophils (PMN) and the presence of high concentration of human neutrophil peptides (HNP), both of which are expected to kill the bacteria but fail to do so. The mechanisms remain unknown. Objectives: This study examined several possible mechanisms to understand this paradox. Method: PMN were isolated from sputum and blood of subjects with and without CF or non-CF bronchiectasis for phagocytic assays. HNP isolated from CF patients were used to stimulate healthy PMN followed by phagocytic tests. Measurements and Main Results: PMN isolated from the sputum of the bronchiectatic patients display defective phagocytosis that correlated with high concentrations of HNP in the lung. When healthy PMN were incubated with HNP, decreased phagocytic capacity was observed in association with depressed surface Fcγ RIII, actin-filament remodeling, enhanced intracellular Ca2+, and degranulation. Treatment of PMN with an intracellular Ca2+ blocker or α1-proteinase inhibitor to attenuate the activity of HNP largely prevented the HNP-induced phagocytic deficiency. Intratracheal instillation of HNP in Pallid mice (genetically deficient in α1-proteinase inhibitor) resulted in a greater PMN lung infiltration and phagocytic deficiency compared to wild type mice. Conclusions: HNP or PMN alone exert antimicrobial ability which was lost as a result of their interaction. These effects of HNP may help explain the clinical paradox seen in patients with inflammatory lung diseases, suggesting HNP as a novel target for clinical therapy. Key words: inflammation innate immunity lung injury
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||